Clinical relevance of systemic and local IGF-I: Lessons from animal models

Pediatric Endocrinology Reviews

Volumn 5, Issue SUPPL. 2, 2008, Pages 739-743

  LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Growth; IGF I; Insulin like growth factor; Metabolism

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

AUTOCRINE EFFECT; ENDOCRINE FUNCTION; GENE DELETION; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

ANIMALS; BONE DENSITY; GROWTH; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, KNOCKOUT; MODELS, ANIMAL;

EID: 41549083742     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74
2. Yakar S, Rosen CJ. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 2003;228:245-252
3. Yakar S, Liu JL, Le Roith D. The growth hormone/insulin-like growth factor-I system: implications for organ growth and development. Pediatr Nephrol 2000;14:544-549
4. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324-7329
5. Sjogren K, Wallenius K, Liu JL, Bohlooly YM, Pacini G, Svensson L, Tornell J, Isaksson OG, Ahren B, Jansson JO, Ohlsson C. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001;50:1539-1545
6. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50:1110-1118
7. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004;113:96-105
8. Foss MC, Saad MJ, Paccola GM, Paula FJ, Piccinato CE, Moreira AC. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991;72:1048-1053
9. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986;250:E269-273
10. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001;86:478-481
11. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002;110:771-781
12. Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 2003;52:2483-2489